E. Demirci Et Al. , "Lu-177-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update," NUCLEAR MEDICINE COMMUNICATIONS , vol.39, no.8, pp.789-796, 2018
Demirci, E. Et Al. 2018. Lu-177-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update. NUCLEAR MEDICINE COMMUNICATIONS , vol.39, no.8 , 789-796.
Demirci, E., Kabasakal, L., Toklu, T., Ocak, M., Şahin, O. A., Alan-Selcuk, N., ... Araman, A.(2018). Lu-177-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update. NUCLEAR MEDICINE COMMUNICATIONS , vol.39, no.8, 789-796.
Demirci, Emre Et Al. "Lu-177-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update," NUCLEAR MEDICINE COMMUNICATIONS , vol.39, no.8, 789-796, 2018
Demirci, Emre Et Al. "Lu-177-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update." NUCLEAR MEDICINE COMMUNICATIONS , vol.39, no.8, pp.789-796, 2018
Demirci, E. Et Al. (2018) . "Lu-177-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update." NUCLEAR MEDICINE COMMUNICATIONS , vol.39, no.8, pp.789-796.
@article{article, author={Emre Demirci Et Al. }, title={Lu-177-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update}, journal={NUCLEAR MEDICINE COMMUNICATIONS}, year=2018, pages={789-796} }